BioSig (BSGM) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 14, 2021
Document Information Line Items
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Trading Symbol	BSGM
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		32,180,479
Amendment Flag	false
Entity Central Index Key	0001530766
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-38659
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4333375
Entity Address, Address Line One	54 Wilton Road, 2nd Floor
Entity Address, City or Town	Westport
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06880
City Area Code	(203)
Local Phone Number	409-5444
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 22,474,866	$ 28,268,000
Inventory	649,937	768,319
Prepaid expenses and vendor deposits	209,000	301,000
Total current assets	23,333,549	29,337,000
Property and equipment, net	381,401	288,560
Right-to-use assets, net	356,266	306,484
Patents, net	341,000	346,000
Trademarks	1,000	1,000
Prepaid expenses, long term	1,000	5,000
Deposits	102,000	102,000
Total assets	24,516,000	30,386,000
Current liabilities:
Accounts payable and accrued expenses, including $147 and $317 to related parties as of March 31, 2021 and December 31, 2020, respectively	3,459,035	4,722,137
Deferred revenue, short term	32,156	0
Dividends payable	75,000	73,000
Lease liability, short term	329,924	312,691
Total current liabilities	3,896,000	5,108,000
Deferred revenue, long term	29,476	0
Lease liability, long term	28,110	720
Total long-term debt	57,000	1,000
Total liabilities	3,953,000	5,109,000
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of March 31, 2021 and December 31, 2020	105,000	105,000
Equity:
Preferred stock,	0	0
Common stock, $0.001 par value, authorized 200,000,000 shares, 32,114,781 and 30,764,792 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	32,000	31,000
Additional paid in capital	185,168,000	181,344,000
Accumulated deficit	(165,324,000)	(157,005,000)
Total stockholders' equity (deficit)	19,876,000	24,370,000
Non-controlling interest	582,388	802,269
Total equity	20,458,000	25,172,000
Total liabilities and stockholders' equity (deficit)	$ 24,516,000	$ 30,386,000

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accounts payable and accrued expenses, related parties (in Dollars)	$ 147	$ 317
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	32,114,781	30,764,792
Common stock, shares outstanding	32,114,781	30,764,792
Series C Preferred Stock [Member]
Preferred stock, shares issued	105	105
Preferred stock, shares outstanding	105	105
Preferred stock, liquidation preference (in Dollars)	$ 105	$ 105
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series D Preferred Stock [Member]
Preferred stock, shares authorized	1,400	1,400
Series E Preferred Stock [Member]
Preferred stock, shares authorized	1,000	1,000
Series F Preferred Stock [Member]
Preferred stock, shares authorized	200,000	200,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 118,047	$ 0
Cost of goods sold	98,618	0
Gross profit	19,429	0
Research and development	1,265,707	4,926,714
General and administrative	7,271,461	7,855,220
Depreciation and amortization	42,000	21,000
Total operating expenses	8,578,753	12,802,949
Loss from operations	(8,560,000)	(12,803,000)
Interest income, net	1,000	40,000
Loss before income taxes	(8,559,000)	(12,763,000)
Income taxes (benefit)	0	0
Net loss	(8,559,000)	(12,763,000)
Non-controlling interest	239,421	1,428,000
Net loss attributable to BioSig Technologies, Inc.	(8,319,000)	(11,335,000)
Preferred stock dividend	(2,000)	(5,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (8,321,000)	$ (11,340,000)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.26)	$ (0.46)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	31,584,142	24,389,249
Product [Member]
Revenue	$ 115,367	$ 0
Service [Member]
Revenue	$ 2,680	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	At-the-Market Offering [Member]Series D Preferred Stock [Member]Common Stock [Member]	At-the-Market Offering [Member]Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	At-the-Market Offering [Member]	Settlement of Preferred Stock [Member]Series D Preferred Stock [Member]Common Stock [Member]	Settlement of Preferred Stock [Member]Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Settlement of Preferred Stock [Member]Series C Preferred Stock [Member]	Cashless Exercise of Warrants [Member]Series D Preferred Stock [Member]Common Stock [Member]	Exercise of Warrants [Member]Series D Preferred Stock [Member]Common Stock [Member]	Exercise of Warrants [Member]Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Exercise of Warrants [Member]	Trek Therapeutics, PBC [Member]Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Trek Therapeutics, PBC [Member]Noncontrolling Interest [Member]	Trek Therapeutics, PBC [Member]	Series D Preferred Stock [Member]Common Stock [Member]	Series E Preferred Stock [Member]Additional Paid-in Capital [Member]	Series E Preferred Stock [Member]Retained Earnings [Member]	Series C Preferred Stock [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2019														$ 23	$ 115,910	$ (104,787)		$ 515	$ 11,661
Balance (in Shares) at Dec. 31, 2019														23,323,087
Common stock issued upon exercise of options (in Shares)														11,141
Sale of common stock														$ 2	9,050				9,052
Sale of common stock (in Shares)														2,500,000
Common stock issued upon conversion of preferred stock and accrued dividends					$ 6	$ 6									10		$ 10
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)				1,083										2,667
Common stock issued upon exercise of warrants								$ 1	$ 301	$ 302
Common stock issued upon exercise of warrants (in Shares)							10,574	80,432
Fair value of subsidiary shares issued to acquire research and development											$ 2,440	$ 735	$ 3,175
Stock based compensation															3,628			785	4,413
Stock based compensation (in Shares)														81,334
Preferred Stock dividend															(5)				(5)
Net loss																(11,335)		(1,428)	(12,763)
Balance at Mar. 31, 2020														$ 26	131,340	(116,122)		607	15,851
Balance (in Shares) at Mar. 31, 2020														26,010,318
Balance at Dec. 31, 2020														$ 31	181,344	(157,005)		802	$ 25,172
Balance (in Shares) at Dec. 31, 2020														30,764,792					30,764,792
Common stock issued for services															1,777				$ 1,777
Common stock issued for services (in Shares)														406,692					406,692
Common stock issued upon exercise of options															28				$ 28
Common stock issued upon exercise of options (in Shares)														9,375					9,375
Sale of common stock		$ 1,300	$ 1,300
Sale of common stock (in Shares)	251,720
Stock based compensation														$ 1	721			20	$ 742
Stock based compensation (in Shares)														682,202
Preferred Stock dividend															(2)				(2)
Net loss																(8,319)		(240)	(8,559)
Balance at Mar. 31, 2021														$ 32	$ 185,168	$ (165,324)		$ 582	$ 20,458
Balance (in Shares) at Mar. 31, 2021														32,114,781					32,114,781

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Options, per share	$ 2.96
Series D Preferred Stock [Member] | Common Stock [Member]
Options, per share	$ 2.96
Preferred Stock, per share		$ 3.75
At-the-Market Offering [Member]
Sale of common stock under At-the-market offering, transaction expenses (in Dollars)	$ 40,000
Settlement of Preferred Stock [Member] | Series D Preferred Stock [Member] | Common Stock [Member]
Preferred Stock, per share		5.39
Exercise of Warrants [Member] | Series D Preferred Stock [Member] | Common Stock [Member]
Warrants, per share		$ 3.75

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (8,559)	$ (12,763)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	42	21
Amortization of right to use assets	111	113
Equity based compensation	2,519	4,413
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC	0	3,174
Changes in operating assets and liabilities:
Inventory	118	(222)
Vendor deposits	18	(100)
Prepaid expenses	78	(10)
Payment of long term deposit	61	0
Accounts payable	(1,263)	(456)
Operating lease liabilities	(116)	(112)
Net cash used in operating activities	(6,991)	(5,942)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(130)	(20)
Net cash used in investing activity	(130)	(20)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	0	9,052
Proceeds from sale of common stock under a At-the-market offering, net of issuance costs	1,300	0
Proceeds from exercise of options	28	0
Proceeds from exercise of warrants	0	302
Net cash provided by financing activities	1,328	9,354
Net increase in cash and cash equivalents	(5,793)	3,392
Cash and cash equivalents, beginning of the period	28,268	12,108
Cash and cash equivalents, end of the period	22,475	15,500
Cash paid during the period for interest	0	0
Cash paid during the period for income taxes	0	0
Noncash investing and financing activities:
Dividend payable on preferred stock charged to additional paid in capital	2	5
Record right-to-use assets and related lease liability	218	0
Series C Preferred Stock [Member]
Noncash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	$ 0	$ 16

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 NATURE OF OPERATIONS AND BASIS OF PRESENTATION BioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard of care in electrophysiology with its initial product offering, the PURE EP™ System, designed for enhanced cardiac signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage. On November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was renamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. As of March 31, 2021, ViralClear had been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. In 2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $15.6 million and issued an aggregate of 894,869 shares of its common stock in connection with acquiring assets and with know-how agreements. As of March 31, 2021, the Company had a majority interest in ViralClear of 70.2%. On July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation. The unaudited condensed consolidated financial statements include the accounts of BioSig Technologies, Inc., its wholly owned subsidiary, NeuroClear Technologies, Inc. and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. as the “Company” or “BioSig”. The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements. Operating results for the three months ended March 31, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 15, 2021. COVID-19 On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The full public-health impact of the ongoing pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely affected and may continue to adversely affect the global economy, resulting in delaying to our commercialization objectives of the PURE EP Systems into 2021.

MANAGEMENT_S LIQUIDITY PLANS

MANAGEMENT’S LIQUIDITY PLANS	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 MANAGEMENT S LIQUIDITY PLANS BioSig Technologies, Inc.’s primary efforts are principally devoted to improving the standard care of electrophysiology with its PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias; NeuroClear’s and ViralClear’s efforts are in developing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company has generated minimal revenues and there is no assurance that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's ongoing research and development will be successfully completed or that any product will be commercially viable. At March 31, 2021, the Company had working capital of approximately $19.4 million. During the three months ended March 31, 2021, the Company raised approximately $1.3 million, net of expenses, through an At-the-market offering. At March 31, 2021 the Company has effective Forms S-3, shelf registration statements for an aggregate of $116.0 million. At March 31, 2021, the Company had cash of approximately $22.5 million, which constitutes sufficient funds for the Company to meet its commercialization efforts, research and development and other funding requirements for at least the next 12 months from the date of issuance of these unaudited financial statements.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of long-term operating leases, patent capitalization, fair value of acquired assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers The Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s unaudited condensed consolidated balance sheet. A reconciliation of contract liabilities with customers is presented below: Balance at December 31, 2020 Consideration Received Recognized in Revenue Balance at March 31, 2021 Product revenue $ - $ 115,367 $ (115,367 ) $ - Service revenue - 64,312 (2,680 ) 61,632 Total $ - $ 179,679 $ (118,047 ) $ 61,632 The table below summarizes our deferred revenue as of March 31, 2021 and December 31, 2020: March 31, 2021 December 31, 2020 Deferred revenue-current $ 32,156 $ - Deferred revenue-noncurrent 29,476 - Total deferred revenue $ 61,632 $ - We had one customer which accounted for approximately 100% of our revenue in the three months ended March 31, 2021. Cost of Goods Sold Cost of goods sold consists primarily of the delivered cost of our medical device(s) sold. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2021 and December 31, 2020, deposits in excess of FDIC limits were $22.0 million and $27.8 million, respectively. Inventory The inventory is comprised of finished goods available for sale and are stated at the lower of cost or net realizable value using the first-in, first-out method of valuation. The inventory at March 31, 2021 and December 31, 2020 were $649,937 and $768,319, respectively. Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments. Leases The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets used in operations during the three months ended March 31, 2021 and 2020. Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1.3 million and $4.9 million for the three months ended March 31, 2021 and 2020, respectively. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2021 March 31, 2020 Series C convertible preferred stock 47,659 81,465 Options to purchase common stock 3,780,037 3,828,896 Warrants to purchase common stock 1,436,200 1,963,030 Restricted stock units to acquire common stock 346,000 181,334 Totals 5,609,896 6,054,725 Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the financial statements. Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the three months ended March 31, 2021 and 2020, the Company recorded amortization of $4,751 and $4,751 to current period operations, respectively. Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ViralClear Pharmaceuticals, Inc. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated statements of operations. The Company’s equity interest in ViralClear is 70.2% and the non-controlling stockholders’ interest is 29.8% as of March 31, 2021. This is reflected in the consolidated statements of equity. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting). Reclassifications Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2021 and December 31, 2020 is summarized as follows: March 31, 2021 December 31, 2020 Computer equipment $ 315,532 $ 232,902 Furniture and fixtures 79,147 75,127 Manufacturing equipment 34,377 34,377 Testing/Demo equipment 139,225 96,000 Total 568,281 438,406 Less accumulated depreciation (186,880 ) (149,846 ) Property and equipment, net $ 381,401 $ 288,560 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $36,834 and $16,264 for three months ended March 31, 2021 and 2020, respectively.

RIGHT TO USE ASSETS AND LEASE L

RIGHT TO USE ASSETS AND LEASE LIABILITY	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	NOTE 5 RIGHT TO USE ASSETS AND LEASE LIABILITY Operating leases: On February 10, 2021 the Company entered into a Sixth Amendment to the Office Lease at 12424 Wilshire Blvd in Los Angeles dated August 9, 2011 – it is the Fourth Extended Term with respect to Suite 745 and the Expansion Term with respect to Suite 740 which is from July 1, 2021 until June 30, 2022 with a fixed monthly rent equal to $13,702 (down from $16,289); and the security deposit will be reduced by $5,448 so that the balance remaining shall be $27,404. The Company determined that the Sixth Amendment was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted the right-to-use asset. At February 10, 2021 the Company removed the remaining right-to-use net assets of $60,881 and related lease liability of $63,076 and recorded right-to-use assets and related lease liability of $217,903. On October 1, 2019, the Company entered into a lease agreement whereby the Company leased approximately 1,400 square feet of office space in Rochester, Minnesota commencing November 1, 2019 and expiring on October 31, 2021 at an initial rate of $3,411 per month with escalating payments. The lease agreement includes an option to extend the lease for two additional periods of two years each past its initial term. At lease modification date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8%. As of March 31, 2021, the Company had outstanding five leases with aggregate payments of $38,535 per month, expiring through December 31, 2022. Right to use assets is summarized below: March 31, 2021 December 31, 2020 Right to use assets, net $ 808,511 $ 1,087,075 Less accumulated depreciation (452,245 ) (780,591 ) Right to use assets, net $ 356,266 $ 306,484 During the three months ended March 31, 2021 and 2020, the Company recorded $118,601 and $119,408 as lease expense to current period operations, respectively. Lease liability is summarized below: March 31, 2021 December 31, 2020 Total lease liability $ 358,034 $ 313,411 Less: short term portion (329,924 ) (312,691 ) Long term portion $ 28,110 $ 720 Maturity analysis under these lease agreements are as follows: Remainder of 2021 $ 289,195 Year ended December 31, 2022 83,412 Total 372,607 Less: Present value discount (14,573 ) Lease liability $ 358,034 Lease expense for the three months ended March 31, 2021 and 2020 was comprised of the following: March 31, 2021 March 31, 2020 Operating lease expense $ 110,932 $ 113,262 Short-term lease expense 7,429 5,655 Variable lease expense 240 491 Total $ 118,601 $ 119,408

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at March 31, 2021 and December 31, 2020 consist of the following: March 31, 2021 December 31, 2020 Accrued accounting and legal $ 188,556 $ 176,735 Accrued reimbursements and travel 25,072 55,836 Accrued consulting 157,102 255,693 Accrued research and development expenses 2,411,067 3,127,404 Accrued product purchases 4,663 30,350 Accrued marketing 119,061 - Accrued office and other 91,926 127,315 Accrued payroll 448,255 935,471 Accrued settlement related to arbitration 13,333 13,333 $ 3,459,035 $ 4,722,137

SERIES C 9% CONVERTIBLE PREFERR

SERIES C 9% CONVERTIBLE PREFERRED STOCK	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 7 SERIES C 9% CONVERTIBLE PREFERRED STOCK Series C 9% Convertible Preferred Stock On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. As a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of March 31, 2021 and December 31, 2020 was $3.75 per share, subject to certain reset provisions. The Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of March 31, 2021, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation the Company may not have the ability to meet at the time of such demand. The Company will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law. Accordingly, the Company has classified the Series C Preferred Stock as a mezzanine obligation in the accompanying consolidated balance sheets. Series C Preferred Stock issued and outstanding totaled 105 as of March 31, 2021 and December 31, 2020. As of March 31, 2021 and December 31, 2020, the Company has accrued $74,547 and $72,217 dividends payable on the Series C Preferred Stock.

STOCKHOLDER EQUITY

STOCKHOLDER EQUITY	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 8 STOCKHOLDER EQUITY Shareholder rights plan On July 14, 2020, our board of directors adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock, par value $0.001 per share, for an exercise price of $50.00, once the rights become exercisable. In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights will expire on July 13, 2021, unless terminated earlier by our board of directors. Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2021, and December 31, 2020, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As of March 31, 2021, and December 31, 2020, there were no outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock. Common stock BioSig Technologies, Inc. The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of March 31, 2021 and December 31, 2020, the Company had 32,114,781 and 30,764,792 shares issued and outstanding, respectively. In January 2021, the Company issued an aggregate of 658,868 shares of its common stock for services at a fair value previously recorded in 2020 of $2,658,224. During the three months ended March 31, 2021, the Company issued 406,692 shares of common stock for services at a fair value of $1,777,619. During the three months ended March 31, 2021, the Company issued 9,375 shares of common stock in exchange for proceeds of $27,750 from the exercise of options. During the three months ended March 31, 2021, the Company issued an aggregate of 23,334 shares of its common stock for vested restricted stock units as stock-based compensation. Open Market Sale Agreement On August 28, 2020, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC to act as the Company’s sales agent and/or principal (“Jefferies” or the “Agent”), with respect to the issuance and sale of up to $45.0 million of the Company’s shares of common stock (the “Shares”) from time to time in an at-the-market offering. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the common stock in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of the Shares under the Sales Agreement. The Company or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. Jefferies will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq. The Company paid Agent a commission equal to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Jefferies with customary indemnification and contribution rights. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms. The common stock was sold and issued pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-230448), which was previously declared effective by the Securities and Exchange Commission, and a related prospectus. From January 15, 2021 through February 16, 2021, the Company sold 251,720 shares of its common stock through the Open Market Sales Agreement for net proceeds of $1,300,135, after transactional costs of $40,365. On March 25, 2021, the Company delivered written notice to Jefferies to terminate the Sales Agreement effective as of April 8, 2021, pursuant to Section 7(b)(i) thereof. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.

OPTIONS, RESTRICTED STOCK UNITS

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS BioSig Technologies, Inc. 2012 Equity Incentive Plan On October 19, 2012, the Board of Directors of BioSig Technologies, Inc. approved the 2012 Equity Incentive Plan (“the “Plan”) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 11,974,450 (as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are 1,535,565 shares remaining available for future issuance of awards under the terms of the Plan as of March 31, 2021. Options Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the three months ended March 31, 2021 was estimated using the Black-Scholes pricing model. During the three months ended March 31, 2021, the Company granted an aggregate of 489,500 options to officers, directors and key consultants. The following table presents information related to stock options at March 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.51-5.00 2,187,257 8.1 1,499,428 5.01-7.50 1,324,447 6.3 980,179 7.51-10.00 203,333 8.5 100,273 10.01-12.50 65,000 9.1 46,249 3,780,037 7.5 2,626,129 A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2020 3,568,497 $ 5.59 7.0 $ 110,961 Grants 489,500 4.38 10.0 $ - Exercised (9,375 ) $ 2.96 - Forfeited/expired (268,585 ) $ 7.53 - Outstanding at March 31, 2021 3,780,037 $ 5.31 7.50 $ 308,891 Exercisable at March 31, 2021 2,626,129 $ 5.34 6.77 $ 228,066 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig Technologies, Inc. of $4.31 as of March 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date. On January 12, 2021, BioSig Technologies, Inc. granted 387,500 options to purchase the company stock in connection with the services rendered at the exercise price of $4.23 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years. On February 16, 2021, BioSig Technologies, Inc. granted 102,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.97 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years. The following assumptions were used in determining the fair value of options during the three months ended March 31, 2021: Risk-free interest rate 0.83% - 0.94 % Dividend yield 0 % Stock price volatility 94.06% to 95.98 % Expected life 6 years Weighted average grant date fair value $ 4.03 The fair value of all options vesting during the three months ended March 31, 2021 and 2020 of $576,885 and $623,693, respectively, was charged to current period operations. Unrecognized compensation expense of $4,349,976 at March 31, 2021 will be expensed in future periods. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at March 31, 2021: Exercise Number Expiration Price Outstanding Date $ 4.38 548,938 April 2021 $ 4.80 125,000 February 2025 $ 6.16 568,910 November 2027 $ 6.85 193,352 July 2021 to August 2021 1,436,200 A summary of the warrant activity for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Contractual Aggregate Shares Exercise Price Term Intrinsic Value Outstanding at December 31, 2020 1,446,200 $ 5.44 3.3 $ 1,500 Grants - Exercised - Expired (10,000 ) $ 3.75 - - Outstanding at March 31, 2021 1,436,200 $ 5.45 3.1 $ - Vested and expected to vest at March 31, 2021 1,436,200 $ 5.45 3.1 $ - Exercisable at March 31, 2021 1,436,200 $ 5.45 3.1 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the company’s stock price of $4.31 of March 31, 2021, which would have been received by the option holders had those option holders exercised their options as of that date. Restricted Stock Units The following table summarizes the restricted stock activity for the three months ended March 31, 2021: Restricted shares issued as of December 31, 2020 218,334 Granted 251,000 Vested and issued (23,334 ) Forfeited (100,000 ) Vested restricted shares as of March 31, 2021 - Unvested restricted shares as of March 31, 2021 346,000 On January 4, 2021, the Company granted 220,000 restricted stock units for services with 105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year. On March 8, 2021 the Company granted 31,000 restricted stock units for services vesting on August 31, 2021. Stock based compensation expense related to restricted stock grants was $99,120 and $401,478 for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the stock-based compensation relating to restricted stock of $1,128,853 remains unamortized. ViralClear Pharmaceuticals, Inc. 2019 Long-Term Incentive Plan On September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear Plan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 shares of ViralClear’s common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of the ViralClear Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonstatutory options. The Board of Directors of ViralClear or a committee thereof administers the ViralClear Plan and determines the exercise price, vesting and expiration period of the grants under the ViralClear Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith. Additionally, the vesting period of the grants under the ViralClear Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are 1,987,000 shares remaining available for future issuance of awards under the terms of the ViralClear Plan. ViralClear Options A summary of the stock option activity and related information for the ViralClear Plan for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Contractual Shares Exercise Price Term Outstanding at December 31, 2020 1,527,666 $ 5.00 3.96 Grants - Exercised - Forfeited/expired (852,666 ) $ 5.00 Outstanding at March 31, 2021 675,000 $ 5.00 8.61 Exercisable at March 31, 2021 608,332 $ 5.00 8.57 The following table presents information related to stock options at March 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 675,000 8.61 608,332 The fair value of the stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities with the market value of stock price based on recent sales. The Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of all options vesting during the three months ended March 31, 2021 and 2020 of $36,521 and $0, respectively, was charged to current period operations. Unrecognized compensation expense of $292,166 at March 31, 2021 will be expensed in future periods. Warrants (ViralClear) The following table presents information related to warrants (ViralClear) at March 31, 2021: Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347 Restricted stock units (ViralClear) The following table summarizes the restricted stock activity for the three months ended March 31, 2021: Restricted shares issued as of December 31, 2020 1,420,716 Granted - Forfeited (82,716 ) Total 1,338,000 Comprised of: Vested restricted shares as of March 31, 2021 698,000 Unvested restricted shares as of March 31, 2021 640,000 Stock based compensation expense related to restricted stock unit grants of ViralClear was $29,151 and $3,387,413 for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the stock-based compensation relating to restricted stock of $851,839 remains unamortized.

NON-CONTROLLING INTEREST

NON-CONTROLLING INTEREST	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Noncontrolling Interest Disclosure [Text Block]	NOTE 10 NON-CONTROLLING INTEREST On November 7, 2018, the Company formed ViralClear Pharmaceuticals, Inc., a Delaware Corporation, formerly known as NeuroClear Technologies, Inc. for the purpose to pursue additional applications of the PURE EP™ signal processing technology outside of electrophysiology and subsequently in 2020 was repurposed to develop a broad-spectrum anti-viral agent that had potential against the COVID-19 virus. In late 2020, ViralClear again was repurposed back to pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. As of March 31, 2021 and December 31, 2020, the Company had a majority interest in ViralClear of 70.2%. A reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the three months ended March 31, 2021: Net loss $ (804,642 ) Average Non-controlling interest percentage of profit/losses 29.8 % Net loss attributable to the non-controlling interest $ (239,421 ) Net loss attributable to the non-controlling interest for the three months ended March 31, 2020: Net loss $ (7,621,328 ) Average Non-controlling interest percentage of profit/losses 18.7 % Net loss attributable to the non-controlling interest $ (1,427,813 ) The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2021: Balance, December 31, 2020 $ 802,269 Allocation of equity to non-controlling interest due to equity-based compensation issued 19,540 Net loss attributable to non-controlling interest (239,421 ) Balance, March 31, 2021 $ 582,388

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS AND CONTINGENCIES Licensing agreements 2017 Know-How License Agreement On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date. The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined. Patent and Know-How License Agreement EP Software Agreement On November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and import licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company. In connection with the EP Software Agreement, the Company issued to Mayo an 8-year warrant (the “EP Software Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The EP Software Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the EP Software Warrant. The Company agreed to pay Mayo an upfront consideration of $25,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $625,000 in aggregate. Amended and Restated Patent and Know-How License Agreement Tools Agreement On November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of electrophysiology systems. In connection with the Tools Agreement, the Company issued to Mayo an 8-year warrant (the “Tools Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The Tools Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the Tools Warrant. The Company agreed to pay Mayo an upfront consideration of $100,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $550,000 in aggregate. ViralClear Patent and Know-How License Agreement On November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias in the autonomic nervous system. In connection with the ViralClear Agreement, NeuroClear issued to Mayo an 8-year warrant (the “ViralClear Warrant”) to purchase 473,772 shares of ViralClear’s common stock at an exercise price of $5.00 per share. The ViralClear Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the ViralClear Warrant. ViralClear agreed to pay Mayo an upfront consideration of $50,000. ViralClear also agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $700,000 in aggregate. Trek Therapeutics, PBC In the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received. As part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments. 3LP Advisors LLC (d/b/a Sherpa Technology Group) On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested. The SOW has been extended through 2021 at a monthly rate of $15,000 per month. Mr. Filler is the general counsel and partner of Sherpa. During the three months ended March 31, 2021 and 2020, the Company paid $45,000 and $104,363 as patent costs, consulting fees and expense reimbursements. As of March 31, 2021 and December 31, 2020, there was an unpaid balance of $15,000 and $15,000, respectively. Defined Contribution Plan Effective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the three months ended March 31, 2021 and 2020, the Company charged operations $71,465 and $38,201 for contributions under the 401(k) Plan. Purchase commitments As of March 31, 2021, the Company had aggregate purchase commitments of approximately $2,920,830 for future services or products, some of which are subject to modification or cancellations. Litigation Aurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc. On January 8, 2021, Aurigene Pharmaceutical Services, LTD (“Aurigene”) filed a complaint with the United States District Court for the District of Connecticut claiming the Company is in default of certain milestone payments for manufacturing and services under contracts dated June 23, 2020 and July 16, 2020 in aggregate amount of $1,530,000. The Company contends that it is not a proper party to the lawsuit since the agreements at issue were signed by a subsidiary. The Company also contends that Aurigene is not entitled to the relief it seeks, because it did not meet its own obligations under the contracts, including several manufacturing milestones. The Company intends to defend itself vigorously. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

SEGMENT REPORTING

SEGMENT REPORTING	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	NOTE 12 SEGMENT REPORTING In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has three reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc. Information concerning the operations of the Company’s reportable segments is as follows: Summary Unaudited condensed consolidated Statement of Operations for the three months ended March 31, 2021: BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Revenue: Product sales $ 115,367 $ - $ - $ 115,367 Service 2,680 - - 2,680 Total Revenue 118,047 - - 118,047 Cost of goods sold 98,618 - - 98,618 Gross profit 19,429 - - 19,429 Operating expenses: Research and development 1,275,993 (10,286 ) - 1,265,707 General and administrative 6,456,625 814,386 450 7,271,461 Depreciation and amortization 40,728 857 - 41,585 Total operating expenses 7,773,346 804,957 450 8,578,753 Loss from operations (7,753,917 ) (804,957 ) (450 ) (8,559,324 ) Other income: Interest income and other income, net 606 114 - 720 Net loss $ (7,753,311 ) $ (804,843 ) $ (450 ) $ (8,558,604 ) Summary Unaudited condensed consolidated Statement of Operations for the three months ended March 31, 2020: BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Operating expenses: Research and development $ 1,327,003 $ 3,599,711 $ - $ 4,926,714 General and administrative 3,819,438 4,035,782 - 7,855,220 Depreciation and amortization 21,015 - - 21,015 Total operating expenses 5,167,456 7,635,493 - 12,802,949 Loss from operations (5,167,456 ) (7,635,493 ) - (12,802,949 ) Other income: Interest income and other income, net 25,411 14,165 - 39,576 Net loss $ (5,142,045 ) $ (7,621,328 ) $ - $ (12,763,373 ) Summary of assets at March 31, 2021: BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Cash $ 18,060,472 $ 4,414,394 $ - $ 22,474,866 Inventory 649,937 - - 649,937 Other current assets 203,757 4,989 - 208,746 Total operating assets 18,914,166 4,419,383 - 23,333,549 Property and equipment, net 373,684 7,717 - 381,401 Right-to-use assets, net 356,266 - - 356,266 Other assets 444,743 - - 444,743 Total assets $ 20,088,859 $ 4,427,100 $ - $ 24,515,959

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 13 RELATED PARTY TRANSACTIONS At March 31, 2021 and December 31, 2020, the Company had reimbursable travel, compensation and other related expenses due related parties of $147,000 and $317,000, respectively. On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 was paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested. Mr. Filler is the general counsel and partner of Sherpa. During the three months ended March 31, 2021 and 2020, the Company paid $45,000 and $75,000 as patent costs, consulting fees and expense reimbursements. As of March 31, 2021 and December 31, 2020, there was an unpaid balance of $15,000 and $15,000, respectively. On January 5, 2021, the Company issued an aggregate of 450,000 shares of common stock to officers of the Company as part of annual compensation.

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 14 FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of March 31, 2021, and December 31, 2020, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures. As of March 31, 2021, and December 31, 2020, the Company did not have any derivative instruments that were designated as hedges. There were no derivative and warrant liability as of March 31, 2021 and December 31, 2020.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 15 SUBSEQUENT EVENTS On April 1, 2021, ViralClear issued 40,000 shares of its common stock for vested restricted stock units. On April 5, 2021, BioSig Technologies, Inc. issued 28,750 shares of its common stock for vested restricted stock units. On April 9, 2021, BioSig Technologies, Inc. granted an aggregate of 90,000 options to purchase shares of its common stock to four employees. The options are exercisable at $4.38 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On April 13, 2021, BioSig Technologies, Inc. granted 25,000 options to purchase shares of its common stock to an employee. The options are exercisable at $4.42 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years. On April 28, 2021, BioSig Technologies, Inc. issued 30,000 shares of its common stock to a consultant for services rendered valued at $110,400. On April 30, 2021, BioSig Technologies, Inc. issued an aggregate of 6,948 shares of its common stock for services.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of long-term operating leases, patent capitalization, fair value of acquired assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Revenue [Policy Text Block]	Revenue Recognition The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system. The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers The Company determines revenue recognition through the following five steps: ● Identify the contract with the customer; ● Identify the performance obligations in the contract; ● Determine the transaction price; ● Allocate the transaction price to the performance obligation in the contract; and ● Recognize revenue when, or as, the performance obligations are satisfied. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations. The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s unaudited condensed consolidated balance sheet. A reconciliation of contract liabilities with customers is presented below: Balance at December 31, 2020 Consideration Received Recognized in Revenue Balance at March 31, 2021 Product revenue $ - $ 115,367 $ (115,367 ) $ - Service revenue - 64,312 (2,680 ) 61,632 Total $ - $ 179,679 $ (118,047 ) $ 61,632 The table below summarizes our deferred revenue as of March 31, 2021 and December 31, 2020: March 31, 2021 December 31, 2020 Deferred revenue-current $ 32,156 $ - Deferred revenue-noncurrent 29,476 - Total deferred revenue $ 61,632 $ - We had one customer which accounted for approximately 100% of our revenue in the three months ended March 31, 2021.
Cost of Goods and Service [Policy Text Block]	Cost of Goods Sold Cost of goods sold consists primarily of the delivered cost of our medical device(s) sold.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At March 31, 2021 and December 31, 2020, deposits in excess of FDIC limits were $22.0 million and $27.8 million, respectively.
Inventory, Policy [Policy Text Block]	Inventory The inventory is comprised of finished goods available for sale and are stated at the lower of cost or net realizable value using the first-in, first-out method of valuation. The inventory at March 31, 2021 and December 31, 2020 were $649,937 and $768,319, respectively.
Prepaid Expenses Policy [Policy Text Block]	Prepaid Expenses and Vendor Deposits Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.
Lessee, Leases [Policy Text Block]	Leases The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets used in operations during the three months ended March 31, 2021 and 2020.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1.3 million and $4.9 million for the three months ended March 31, 2021 and 2020, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of March 31, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2021 March 31, 2020 Series C convertible preferred stock 47,659 81,465 Options to purchase common stock 3,780,037 3,828,896 Warrants to purchase common stock 1,436,200 1,963,030 Restricted stock units to acquire common stock 346,000 181,334 Totals 5,609,896 6,054,725
Share-based Payment Arrangement [Policy Text Block]	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the financial statements.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents, Net The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the three months ended March 31, 2021 and 2020, the Company recorded amortization of $4,751 and $4,751 to current period operations, respectively.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Non-controlling Interest The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ViralClear Pharmaceuticals, Inc. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the consolidated statements of operations. The Company’s equity interest in ViralClear is 70.2% and the non-controlling stockholders’ interest is 29.8% as of March 31, 2021. This is reflected in the consolidated statements of equity.
Segment Reporting, Policy [Policy Text Block]	Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting).
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Disaggregation of Revenue [Table Text Block]	A reconciliation of contract liabilities with customers is presented below: Balance at December 31, 2020 Consideration Received Recognized in Revenue Balance at March 31, 2021 Product revenue $ - $ 115,367 $ (115,367 ) $ - Service revenue - 64,312 (2,680 ) 61,632 Total $ - $ 179,679 $ (118,047 ) $ 61,632
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	The table below summarizes our deferred revenue as of March 31, 2021 and December 31, 2020: March 31, 2021 December 31, 2020 Deferred revenue-current $ 32,156 $ - Deferred revenue-noncurrent 29,476 - Total deferred revenue $ 61,632 $ -
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: March 31, 2021 March 31, 2020 Series C convertible preferred stock 47,659 81,465 Options to purchase common stock 3,780,037 3,828,896 Warrants to purchase common stock 1,436,200 1,963,030 Restricted stock units to acquire common stock 346,000 181,334 Totals 5,609,896 6,054,725

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2021 and December 31, 2020 is summarized as follows: March 31, 2021 December 31, 2020 Computer equipment $ 315,532 $ 232,902 Furniture and fixtures 79,147 75,127 Manufacturing equipment 34,377 34,377 Testing/Demo equipment 139,225 96,000 Total 568,281 438,406 Less accumulated depreciation (186,880 ) (149,846 ) Property and equipment, net $ 381,401 $ 288,560

RIGHT TO USE ASSETS AND LEASE_2

RIGHT TO USE ASSETS AND LEASE LIABILITY (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Text Block [Abstract]
Right to Use Asset [Table Text Block]	Right to use assets is summarized below: March 31, 2021 December 31, 2020 Right to use assets, net $ 808,511 $ 1,087,075 Less accumulated depreciation (452,245 ) (780,591 ) Right to use assets, net $ 356,266 $ 306,484
Lessee, Operating Lease, Disclosure [Table Text Block]	Lease liability is summarized below: March 31, 2021 December 31, 2020 Total lease liability $ 358,034 $ 313,411 Less: short term portion (329,924 ) (312,691 ) Long term portion $ 28,110 $ 720
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Maturity analysis under these lease agreements are as follows: Remainder of 2021 $ 289,195 Year ended December 31, 2022 83,412 Total 372,607 Less: Present value discount (14,573 ) Lease liability $ 358,034
Lease, Cost [Table Text Block]	Lease expense for the three months ended March 31, 2021 and 2020 was comprised of the following: March 31, 2021 March 31, 2020 Operating lease expense $ 110,932 $ 113,262 Short-term lease expense 7,429 5,655 Variable lease expense 240 491 Total $ 118,601 $ 119,408

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at March 31, 2021 and December 31, 2020 consist of the following: March 31, 2021 December 31, 2020 Accrued accounting and legal $ 188,556 $ 176,735 Accrued reimbursements and travel 25,072 55,836 Accrued consulting 157,102 255,693 Accrued research and development expenses 2,411,067 3,127,404 Accrued product purchases 4,663 30,350 Accrued marketing 119,061 - Accrued office and other 91,926 127,315 Accrued payroll 448,255 935,471 Accrued settlement related to arbitration 13,333 13,333 $ 3,459,035 $ 4,722,137

OPTIONS, RESTRICTED STOCK UNI_2

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2021
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) [Line Items]
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2021: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.51-5.00 2,187,257 8.1 1,499,428 5.01-7.50 1,324,447 6.3 980,179 7.51-10.00 203,333 8.5 100,273 10.01-12.50 65,000 9.1 46,249 3,780,037 7.5 2,626,129 Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.00 675,000 8.61 608,332
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at December 31, 2020 3,568,497 $ 5.59 7.0 $ 110,961 Grants 489,500 4.38 10.0 $ - Exercised (9,375 ) $ 2.96 - Forfeited/expired (268,585 ) $ 7.53 - Outstanding at March 31, 2021 3,780,037 $ 5.31 7.50 $ 308,891 Exercisable at March 31, 2021 2,626,129 $ 5.34 6.77 $ 228,066
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following assumptions were used in determining the fair value of options during the three months ended March 31, 2021: Risk-free interest rate 0.83% - 0.94 % Dividend yield 0 % Stock price volatility 94.06% to 95.98 % Expected life 6 years Weighted average grant date fair value $ 4.03
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at March 31, 2021: Exercise Number Expiration Price Outstanding Date $ 4.38 548,938 April 2021 $ 4.80 125,000 February 2025 $ 6.16 568,910 November 2027 $ 6.85 193,352 July 2021 to August 2021 1,436,200
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Contractual Aggregate Shares Exercise Price Term Intrinsic Value Outstanding at December 31, 2020 1,446,200 $ 5.44 3.3 $ 1,500 Grants - Exercised - Expired (10,000 ) $ 3.75 - - Outstanding at March 31, 2021 1,436,200 $ 5.45 3.1 $ - Vested and expected to vest at March 31, 2021 1,436,200 $ 5.45 3.1 $ - Exercisable at March 31, 2021 1,436,200 $ 5.45 3.1 $ -
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the three months ended March 31, 2021: Restricted shares issued as of December 31, 2020 218,334 Granted 251,000 Vested and issued (23,334 ) Forfeited (100,000 ) Vested restricted shares as of March 31, 2021 - Unvested restricted shares as of March 31, 2021 346,000 Restricted shares issued as of December 31, 2020 1,420,716 Granted - Forfeited (82,716 ) Total 1,338,000 Comprised of: Vested restricted shares as of March 31, 2021 698,000 Unvested restricted shares as of March 31, 2021 640,000
Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Table Text Block]	The following table presents information related to warrants (ViralClear) at March 31, 2021: Exercise Number Expiration Price Outstanding Date $ 5.00 473,772 November 2027 10.00 6,575 May 2025 480,347
Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables) [Line Items]
Share-based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity and related information for the ViralClear Plan for the three months ended March 31, 2021 is as follows: Weighted-Average Weighted-Average Remaining Contractual Shares Exercise Price Term Outstanding at December 31, 2020 1,527,666 $ 5.00 3.96 Grants - Exercised - Forfeited/expired (852,666 ) $ 5.00 Outstanding at March 31, 2021 675,000 $ 5.00 8.61 Exercisable at March 31, 2021 608,332 $ 5.00 8.57

NON-CONTROLLING INTEREST (Table

NON-CONTROLLING INTEREST (Tables)	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Schedule of Non-Controlling Interest [Table Text Block]	Net loss attributable to the non-controlling interest for the three months ended March 31, 2021: Net loss $ (804,642 ) Average Non-controlling interest percentage of profit/losses 29.8 % Net loss attributable to the non-controlling interest $ (239,421 ) Net loss $ (7,621,328 ) Average Non-controlling interest percentage of profit/losses 18.7 % Net loss attributable to the non-controlling interest $ (1,427,813 )
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2021: Balance, December 31, 2020 $ 802,269 Allocation of equity to non-controlling interest due to equity-based compensation issued 19,540 Net loss attributable to non-controlling interest (239,421 ) Balance, March 31, 2021 $ 582,388

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information concerning the operations of the Company’s reportable segments is as follows: BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Revenue: Product sales $ 115,367 $ - $ - $ 115,367 Service 2,680 - - 2,680 Total Revenue 118,047 - - 118,047 Cost of goods sold 98,618 - - 98,618 Gross profit 19,429 - - 19,429 Operating expenses: Research and development 1,275,993 (10,286 ) - 1,265,707 General and administrative 6,456,625 814,386 450 7,271,461 Depreciation and amortization 40,728 857 - 41,585 Total operating expenses 7,773,346 804,957 450 8,578,753 Loss from operations (7,753,917 ) (804,957 ) (450 ) (8,559,324 ) Other income: Interest income and other income, net 606 114 - 720 Net loss $ (7,753,311 ) $ (804,843 ) $ (450 ) $ (8,558,604 ) BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Operating expenses: Research and development $ 1,327,003 $ 3,599,711 $ - $ 4,926,714 General and administrative 3,819,438 4,035,782 - 7,855,220 Depreciation and amortization 21,015 - - 21,015 Total operating expenses 5,167,456 7,635,493 - 12,802,949 Loss from operations (5,167,456 ) (7,635,493 ) - (12,802,949 ) Other income: Interest income and other income, net 25,411 14,165 - 39,576 Net loss $ (5,142,045 ) $ (7,621,328 ) $ - $ (12,763,373 ) BioSig Technologies, Inc. ViralClear Pharmaceuticals, Inc. NeuroClear Technologies, Inc. Total Cash $ 18,060,472 $ 4,414,394 $ - $ 22,474,866 Inventory 649,937 - - 649,937 Other current assets 203,757 4,989 - 208,746 Total operating assets 18,914,166 4,419,383 - 23,333,549 Property and equipment, net 373,684 7,717 - 381,401 Right-to-use assets, net 356,266 - - 356,266 Other assets 444,743 - - 444,743 Total assets $ 20,088,859 $ 4,427,100 $ - $ 24,515,959

NATURE OF OPERATIONS AND BASI_2

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) - Viral Clear [Member] $ in Millions	24 Months Ended
	Dec. 31, 2020USD ($)shares
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,965,240
Stock Issued During Period, Value, New Issues (in Dollars) | $	$ 15.6
Stockholders' Equity, Other Shares	894,869
Equity Method Investment, Ownership Percentage	70.20%

MANAGEMENT_S LIQUIDITY PLANS (D

MANAGEMENT’S LIQUIDITY PLANS (Details) - USD ($) $ in Thousands	Aug. 28, 2020	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Working Capital (Deficit)		$ 19,400
At the Market Offering	$ 45,000	116,000
Cash and Cash Equivalents, at Carrying Value		22,475	$ 28,268	$ 15,500	$ 12,108
Series E Preferred Stock [Member]
MANAGEMENT’S LIQUIDITY PLANS (Details) [Line Items]
Proceeds from Sale of Equity Method Investments		$ 1,300

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount	$ 22,000,000		$ 27,800,000
Inventory, Net	649,937		$ 768,319
Research and Development Expense	1,265,707	$ 4,926,714
Amortization	$ 4,751	$ 4,751
Noncontrolling Interest, Ownership Percentage by Parent	70.20%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	29.80%
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Patents [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Disaggregation of Revenue - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Balance	$ 61,632	$ 0
Consideration Received	179,679
Recognized in Revenue	(118,047)
Product [Member]
Disaggregation of Revenue [Line Items]
Balance	0	0
Consideration Received	115,367
Recognized in Revenue	(115,367)
Service [Member]
Disaggregation of Revenue [Line Items]
Balance	61,632	$ 0
Consideration Received	64,312
Recognized in Revenue	$ (2,680)

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Deferred Revenue, by Arrangement, Disclosure - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Deferred Revenue, by Arrangement, Disclosure [Abstract]
Deferred revenue-current	$ 32,156	$ 0
Deferred revenue-noncurrent	29,476	0
Total deferred revenue	$ 61,632	$ 0

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	5,609,896	6,054,725
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	3,780,037	3,828,896
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,436,200	1,963,030
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	346,000	181,334
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	47,659	81,465

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 36,834	$ 16,264
Minimum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

PROPERTY AND EQUIPMENT (Detail

PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 568,281	$ 438,406
Less accumulated depreciation	(186,880)	(149,846)
Property and equipment, net	381,401	288,560
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	315,532	232,902
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	79,147	75,127
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	34,377	34,377
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 139,225	$ 96,000

RIGHT TO USE ASSETS AND LEASE_3

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details)	Feb. 10, 2021USD ($)	Oct. 01, 2019USD ($)ft²	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	$ 13,702	$ 3,411
Operating Lease, Decrease in Monthly Rental	16,289
Increase (Decrease) in Security Deposits	(5,448)
Security Deposit	27,404
Operating Lease, Right-of-Use Asset, Amortization Expense	60,881
Operating Lease, Expense	63,076
Operating Lease, Right-of-Use Asset	217,903		$ 356,266		$ 306,484
Operating Lease, Liability	$ 217,903		358,034		$ 313,411
Area of Real Estate Property (in Square Feet) | ft²		1,400
Operating Leases, Rent Expense			118,601	$ 119,408
Maximum [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Lessee, Operating Lease, Discount Rate		8.00%
Building [Member]
RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			$ 38,535
Lessee, Operating Lease, Option to Extend		The lease agreement includes an option to extend the lease for two additional periods of two years each past its initial term
Number of Leases			5
Lease Expiration Date			Dec. 31, 2022

RIGHT TO USE ASSETS AND LEASE_4

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Right to Use Asset - USD ($)	Mar. 31, 2021	Feb. 10, 2021	Dec. 31, 2020
Right to Use Asset [Abstract]
Right to use assets, net	$ 808,511		$ 1,087,075
Less accumulated depreciation	(452,245)		(780,591)
Right to use assets, net	$ 356,266	$ 217,903	$ 306,484

RIGHT TO USE ASSETS AND LEASE_5

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lessee, Operating Lease, Disclosure - USD ($)	Mar. 31, 2021	Feb. 10, 2021	Dec. 31, 2020
Lessee, Operating Lease, Disclosure [Abstract]
Lease liability	$ 358,034	$ 217,903	$ 313,411
Less: short term portion	(329,924)		(312,691)
Long term portion	$ 28,110		$ 720

RIGHT TO USE ASSETS AND LEASE_6

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Schedule of Future Minimum Rental Payments for Operating Leases - USD ($)	Mar. 31, 2021	Feb. 10, 2021	Dec. 31, 2020
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
Remainder of 2021	$ 289,195
Year ended December 31, 2022	83,412
Total	372,607
Less: Present value discount	(14,573)
Lease liability	$ 358,034	$ 217,903	$ 313,411

RIGHT TO USE ASSETS AND LEASE_7

RIGHT TO USE ASSETS AND LEASE LIABILITY (Details) - Lease, Cost - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease, Cost [Abstract]
Operating lease expense	$ 110,932	$ 113,262
Short-term lease expense	7,429	5,655
Variable lease expense	240	491
Lease Cost	$ 118,601	$ 119,408

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 188,556	$ 176,735
Accrued reimbursements and travel	25,072	55,836
Accrued consulting	157,102	255,693
Accrued research and development expenses	2,411,067	3,127,404
Accrued product purchases	4,663	30,350
Accrued marketing	119,061	0
Accrued office and other	91,926	127,315
Accrued payroll	448,255	935,471
Accrued settlement related to arbitration	13,333	13,333
	$ 3,459,035	$ 4,722,137

SERIES C 9% CONVERTIBLE PREFE_2

SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Jul. 14, 2020	Jan. 09, 2013	Mar. 31, 2021	Dec. 31, 2020	Nov. 20, 2019
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Dividend Payment Terms	declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock
Preferred Stock, Voting Rights	In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights will expire on July 13, 2021, unless terminated earlier by our board of directors
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 3.75	$ 6.16
Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized		4,200
Preferred Stock, Dividend Rate, Percentage		9.00%
Temporary Equity, Par Value		$ 1,000
Preferred Stock, Dividend Payment Terms		payable quarterly
Preferred Stock, Voting Rights		The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description		The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.
Temporary Equity, Shares Issued			105	105
Temporary Equity, Shares Outstanding			105	105
Dividends Payable			$ 74,547	$ 72,217

STOCKHOLDER EQUITY (Details)

STOCKHOLDER EQUITY (Details) - USD ($)	Aug. 28, 2020	Jul. 14, 2020	Jan. 09, 2013	Feb. 16, 2021	Jan. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Dividend Payment Terms		declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001				$ 0.001		$ 0.001	$ 0.001
Preferred Stock, Redemption Price Per Share (in Dollars per share)		$ 50
Preferred Stock, Voting Rights		In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights will expire on July 13, 2021, unless terminated earlier by our board of directors
Preferred Stock, Shares Authorized						1,000,000		1,000,000	1,000,000
Common Stock, Shares, Issued						32,114,781		30,764,792
Stock Issued During Period, Shares, Issued for Services					658,868	406,692
Stock Issued During Period, Value, Issued for Services (in Dollars)					$ 2,658,224	$ 1,777,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						9,375
Proceeds from Stock Options Exercised (in Dollars)						$ 28,000	$ 0
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture						23,334
At the Market Offering (in Dollars)	$ 45,000,000					$ 116,000,000
Commission Rate								3.00%
Stock Issued During Period, Shares, New Issues				251,720
Stock Issued During Period, Value, New Issues (in Dollars)				$ 1,300,135			$ 9,052,000
Payments of Stock Issuance Costs (in Dollars)				$ 40,365
Series A Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						200		200
Series B Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						600		600
Series C Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Dividend Payment Terms			payable quarterly
Preferred Stock, Voting Rights			The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock.  The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Shares Authorized						4,200		4,200
Series D Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						1,400		1,400
Series E Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized						1,000		1,000
Series F Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.001
Preferred Stock, Shares Authorized		200,000,000				200,000		200,000
Exercise of Options [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period						9,375
Proceeds from Stock Options Exercised (in Dollars)						$ 27,750

OPTIONS, RESTRICTED STOCK UNI_3

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - USD ($)	Mar. 08, 2021	Feb. 16, 2021	Jan. 12, 2021	Jan. 04, 2021	Sep. 24, 2019	Mar. 14, 2019	Oct. 19, 2012	Mar. 31, 2021	Mar. 31, 2020
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award					the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)					1,987,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)								489,500
Officers, Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares)								489,500
Share-based Payment Arrangement, Option [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)								1,535,565
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares)			387,500
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)			$ 4.23
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights		one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years	one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years
Share-based Payment Arrangement, Option [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)							11,974,450
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award							the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder
Share Price (in Dollars per share)								$ 4.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								$ 576,885	$ 623,693
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								4,349,976
Share-based Payment Arrangement, Option [Member] | 2012 Equity Incentive Plan [Member] | Maximum [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							10 years
Share-based Payment Arrangement, Option [Member] | Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								292,166
Share-based Payment Arrangement, Noncash Expense								$ 36,521	0
Restricted Stock Units (RSUs) [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in Shares)	31,000			220,000				251,000
Share-based Payment Arrangement, Noncash Expense								$ 99,120	401,478
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount								1,128,853
Restricted Stock Units (RSUs) [Member] | Viral Clear [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Payment Arrangement, Noncash Expense								29,151	$ 3,387,413
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount								$ 851,839
Services Provided [Member] | Share-based Payment Arrangement, Option [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures (in Shares)		102,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)		$ 4.97
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Services Provided [Member] | Share-based Payment Arrangement, Option [Member] | Options at $5.66 [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)						4,000,000

OPTIONS, RESTRICTED STOCK UNI_4

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	3,780,037	3,568,497
Options Outstanding, Weighted Average Remaining Life	7 years 6 months	7 years
Options Exercisable, Number of Options	2,626,129
Options at $2.51-$5.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.51
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 5
Options Outstanding, Number of Options	2,187,257
Options Outstanding, Weighted Average Remaining Life	8 years 1 month 6 days
Options Exercisable, Number of Options	1,499,428
Options at $5.01-$7.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 5.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 7.50
Options Outstanding, Number of Options	1,324,447
Options Outstanding, Weighted Average Remaining Life	6 years 3 months 18 days
Options Exercisable, Number of Options	980,179
Options at $7.51-$10.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 7.51
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 10
Options Outstanding, Number of Options	203,333
Options Outstanding, Weighted Average Remaining Life	8 years 6 months
Options Exercisable, Number of Options	100,273
Options at $10.01 - 12.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 10.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 12.50
Options Outstanding, Number of Options	65,000
Options Outstanding, Weighted Average Remaining Life	9 years 1 month 6 days
Options Exercisable, Number of Options	46,249
Options at $5.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 5
Options Outstanding, Number of Options	675,000
Options Outstanding, Weighted Average Remaining Life	8 years 7 months 9 days
Options Exercisable, Number of Options	608,332

OPTIONS, RESTRICTED STOCK UNI_5

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Outstanding, Shares (in Shares)	3,780,037	3,568,497
Options Outstanding, Weighted-Average Exercise Price	$ 5.31	$ 5.59
Options Outstanding, Weighted-Average Remaining Contractual Term	7 years 6 months	7 years
Options Outstanding, Aggregate Intrinsic Value	$ 308,891	$ 110,961
Options Exercisable, Shares (in Shares)	2,626,129
Options Exercisable, Weighted-Average Exercise Price	$ 5.34
Options Exercisable, Weighted-Average Remaining Contractual Term	6 years 9 months 7 days
Options Exercisable, Aggregate Intrinsic Value (in Dollars)	$ 228,066
Options Granted, Shares (in Shares)	489,500
Options Granted, Weighted-Average Exercise Price	$ 4.38
Options Granted, Weighted-Average Remaining Contractual Term	10 years
Options Exercised, Shares (in Shares)	(9,375)
Options Exercised, Weighted-Average Exercise Price	$ 2.96
Options Canceled, Shares (in Shares)	(268,585)
Options Canceled, Weighted-Average Exercise Price	$ 7.53

OPTIONS, RESTRICTED STOCK UNI_6

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - Share-based Payment Arrangement, Option [Member] - Viral Clear [Member]	3 Months Ended
	Mar. 31, 2021$ / shares
Minimum [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%
Stock price volatility	94.06%
Expected life	6 years
Weighted average grant date fair value (in Dollars per share)	$ 4.03
Maximum [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield	0.00%
Stock price volatility	95.98%
Expected life	6 years
Weighted average grant date fair value (in Dollars per share)	$ 4.03

OPTIONS, RESTRICTED STOCK UNI_7

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Nov. 20, 2019
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)		$ 3.75	$ 6.16
Number of Warrants Outstanding	1,436,200	1,446,200
Warrant at $4.38 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.38
Number of Warrants Outstanding	548,938
Expiration Date, Warrants	April 2021
Warrants at $4.80 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 4.80
Number of Warrants Outstanding	125,000
Expiration Date, Warrants	February 2025
Warrants at $6.16 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 6.16		$ 6.16
Number of Warrants Outstanding	568,910
Expiration Date, Warrants	November 2027
Warrants at $6.85 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 6.85
Number of Warrants Outstanding	193,352
Expiration Date, Warrants	July 2021 to August 2021

OPTIONS, RESTRICTED STOCK UNI_8

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	1,436,200	1,446,200
Warrants Outstanding, Weighted-Average Exercise Price	$ 5.45	$ 5.44
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years 1 month 6 days	3 years 3 months 18 days
Warrants Outstanding, Aggregate Intrinsic Value		$ 1,500
Warrants Vested and expected to vest, Shares	1,436,200
Warrants Vested and expected to vest, Weighted-Average Exercise Price	$ 5.45
Warrants Vested and expected to vest, Weighted-Average Remaining Contractual Term	3 years 1 month 6 days
Warrants Exercisable, Shares	1,436,200
Warrants Exercisable, Weighted-Average Exercise Price	$ 5.45
Warrants Exercisable, Weighted-Average Remaining Contractual Term	3 years 1 month 6 days
Warrants Canceled, Shares	(10,000)
Warrants Canceled, Weighted-Average Exercise Price	$ 3.75

OPTIONS, RESTRICTED STOCK UNI_9

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - shares	Mar. 08, 2021	Jan. 04, 2021	Mar. 31, 2021
Restricted Stock Units (RSUs) [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued			218,334
Restricted shares Granted	31,000	220,000	251,000
Restricted shares Vested			(23,334)
			(100,000)
Vested restricted shares			0
Unvested restricted shares			346,000
Restricted Stock [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued			1,420,716
			(82,716)
Vested restricted shares			698,000
Unvested restricted shares			640,000
Restricted shares issued			1,338,000

OPTIONS, RESTRICTED STOCK UN_10

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Payment Arrangement, Option, Activity - Viral Clear [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Share-based Payment Arrangement, Option, Activity [Line Items]
Options Outstanding, Shares		1,527,666
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 5
Options Outstanding, Weighted-Average Remaining Contractual Term	8 years 7 months 9 days	3 years 11 months 15 days
Exercisable at December 31, 2020	608,332
Exercisable at December 31, 2020 (in Dollars per share)	$ 5
Exercisable at December 31, 2020	8 years 6 months 25 days
Exercised, Shares	0
Forfeited/expired, Shares	(852,666)
Forfeited/expired, Weighted-Average Exercise Price (in Dollars per share)	$ 5
Options Outstanding, Shares	675,000
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 5

OPTIONS, RESTRICTED STOCK UN_11

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range - Viral Clear [Member]	3 Months Ended
	Mar. 31, 2021$ / sharesshares
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Number Outstanding	480,347
Warrants at $5.00 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 5
Number Outstanding	473,772
Expiration Date	November 2027
Warrants $10.00 [Member]
OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, Exercise Price Range [Line Items]
Exercise Price (in Dollars per share) | $ / shares	$ 10
Number Outstanding	6,575
Expiration Date	May 2025

NON-CONTROLLING INTEREST (Detai

NON-CONTROLLING INTEREST (Details)	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Equity Method Investment, Ownership Percentage	70.20%

NON-CONTROLLING INTEREST (Det_2

NON-CONTROLLING INTEREST (Details) - Schedule of Non-Controlling Interest - Viral Clear [Member] - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NON-CONTROLLING INTEREST (Details) - Schedule of Non-Controlling Interest [Line Items]
Net loss	$ (804,642)	$ (7,621,328)
Average Non-controlling interest percentage of profit/losses	29.80%	18.70%
Net loss attributable to the non-controlling interest	$ (239,421)	$ (1,427,813)

NON-CONTROLLING INTEREST (Det_3

NON-CONTROLLING INTEREST (Details) - Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Abstract]
Balance	$ 802,269
Allocation of equity to non-controlling interest due to equity-based compensation issued	19,540
Net loss attributable to non-controlling interest	(239,421)	$ (1,428,000)
Balance	$ 582,388

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Nov. 20, 2019	Nov. 01, 2017	Mar. 15, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term			10 years
Royalty Percentage of Net Sales	10.00%
Warrants and Rights Outstanding, Term	8 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 6.16					$ 3.75
Other Commitment	$ 50,000
Royalty Guarantees, Commitments, Amount	$ 700,000
Agreement, Description		In connection with the SOW, the Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested.
Professional and Contract Services Expense				$ 45,000	$ 104,363
Other Accrued Liabilities				15,000		$ 15,000
Defined Contribution Plan, Cost				71,465	$ 38,201
Long-term Purchase Commitment, Amount				$ 2,920,830
Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales			1.00%
Maximum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Percentage of Net Sales			2.00%
Warrants at $6.16 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 6.16			$ 6.16
Warrants at $5.00 [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Warrants and Rights Outstanding, Term	8 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 5
Class of Warrant or Rights, Granted (in Shares)	473,772
Tools Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment	$ 100,000
Employee Agreement [Member] | Chief Executive Officer [Member] | Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Guarantees, Commitments, Amount	625,000,000,000
Employee Agreement [Member] | Chief Executive Officer [Member] | Annual Salary [Member] | Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment	$ 25,000

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Number of Reportable Segments	3

SEGMENT REPORTING (Details) - S

SEGMENT REPORTING (Details) - Schedule of Segment Reporting Information, by Segment - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Feb. 10, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 118,047	$ 0
Cost of goods sold	98,618	0
Gross profit	19,429	0
Research and development	1,265,707	4,926,714
General and administrative	7,271,461	7,855,220
Depreciation and amortization	41,585	21,015
Total operating expenses	8,578,753	12,802,949
Loss from Operations	(8,559,324)	(12,802,949)
Interest income and other income, net	720	39,576
Net loss	(8,558,604)	(12,763,373)
Cash	22,474,866			$ 28,268,000
Inventory	649,937			768,319
Other current assets	208,746
Total current assets	23,333,549			29,337,000
Property and equipment, net	381,401			288,560
Right-to-use assets, net	356,266		$ 217,903	$ 306,484
Other assets	444,743
Total assets	24,515,959
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue	118,047
Cost of goods sold	98,618
Gross profit	19,429
Research and development	1,275,993	1,327,003
General and administrative	6,456,625	3,819,438
Depreciation and amortization	40,728	21,015
Total operating expenses	7,773,346	5,167,456
Loss from Operations	(7,753,917)	(5,167,456)
Interest income and other income, net	606	25,411
Net loss	(7,753,311)	(5,142,045)
Cash	18,060,472
Inventory	649,937
Other current assets	203,757
Total current assets	18,914,166
Property and equipment, net	373,684
Right-to-use assets, net	356,266
Other assets	444,743
Total assets	20,088,859
Viral Clear [Member]
Segment Reporting Information [Line Items]
Revenue	0
Cost of goods sold	0
Gross profit	0
Research and development	(10,286)	3,599,711
General and administrative	814,386	4,035,782
Depreciation and amortization	857	0
Total operating expenses	804,957	7,635,493
Loss from Operations	(804,957)	(7,635,493)
Interest income and other income, net	114	14,165
Net loss	(804,843)	(7,621,328)
Cash	4,414,394
Inventory	0
Other current assets	4,989
Total current assets	4,419,383
Property and equipment, net	7,717
Right-to-use assets, net	0
Other assets	0
Total assets	4,427,100
NeuroClear Technologies, Inc ("NeuroClear") [Member]
Segment Reporting Information [Line Items]
Revenue	0
Cost of goods sold	0
Gross profit	0
Research and development	0	0
General and administrative	450	0
Depreciation and amortization	0	0
Total operating expenses	450	0
Loss from Operations	(450)	0
Interest income and other income, net	0	0
Net loss	(450)	0
Cash	0
Inventory	0
Other current assets	0
Total current assets	0
Property and equipment, net	0
Right-to-use assets, net	0
Other assets	0
Total assets	0
Product [Member]
Segment Reporting Information [Line Items]
Revenue	115,367	0
Product [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue	115,367
Product [Member] | Viral Clear [Member]
Segment Reporting Information [Line Items]
Revenue	0
Product [Member] | NeuroClear Technologies, Inc ("NeuroClear") [Member]
Segment Reporting Information [Line Items]
Revenue	0
Service [Member]
Segment Reporting Information [Line Items]
Revenue	2,680	$ 0
Service [Member] | Corporate Segment [Member]
Segment Reporting Information [Line Items]
Revenue	2,680
Service [Member] | Viral Clear [Member]
Segment Reporting Information [Line Items]
Revenue	0
Service [Member] | NeuroClear Technologies, Inc ("NeuroClear") [Member]
Segment Reporting Information [Line Items]
Revenue	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	May 17, 2019	Nov. 01, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current			$ 147,000		$ 317,000
Share-based Compensation Arrangement by Share-based Payment Award, Description	the Company entered into a Master Services Agreement with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy
Related Party Transaction, Expenses from Transactions with Related Party			45,000	$ 75,000
Patent Costs, Consulting Fees and Expense Reimbursements [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Accrued Liabilities			$ 15,000		$ 15,000
Affiliated Entity [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction		Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 was paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested.

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member]	Apr. 30, 2021shares	Apr. 28, 2021USD ($)shares	Apr. 13, 2021$ / sharesshares	Apr. 09, 2021$ / sharesshares	Apr. 05, 2021shares	Apr. 01, 2021shares
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	6,948	30,000
Stock Issued During Period, Value, Issued for Services (in Dollars) | $		$ 110,400
Restricted Stock [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross					28,750	40,000
Restricted Stock [Member] | Employees [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Number of Employees				4
Share-based Payment Arrangement, Option [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares			$ 4.42
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Share-based Payment Arrangement, Option [Member] | Employees [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures				90,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares				$ 4.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				2 years